Category: Patent Litigation

    By James DeGiulio — Unigene Secures Ruling of Infringement against Apotex in Fortical Patent Suit Unigene successfully reinstated an earlier 2009 opinion that its two patents for Fortical nasal spray were valid and infringed by Apotex, despite the defendant's argument that affirmative defenses and counterclaims were not addressed in the original order. In 2006,…

    By James DeGiulio — Sanofi, Abbott Successfully Request Sanctions against Glenmark in Tarka Dispute Sanofi and Abbott were successful in their request for sanctions against Glenmark in their patent suit over Tarka, after it was found that Glenmark destroyed evidence relevant to the impending litigation. The dispute began in October 2007, when Glenmark notified…

    By James DeGiulio — Midland Settles with Life Technologies in Fluorescence Probe Infringement Suit Midland Certified Reagent Co. Inc. has resolved an infringement suit brought by Applied Biosystems LLC and parent company Life Technologies Corp. over five patents covering a fluorescence probe used in biotechnology assays. Applied Biosystems and Life Technologies originally filed suit…

    By James DeGiulio — Graceway's Injunction and Nycomed's Dismissal Denied In Aldara Suit Graceway Pharmaceuticals' suit against Nycomed alleging infringement of a patent for skin lesion treatment Aldara continues to move forward, after a ruling denied both defendant Nycomed's motion for dismissal and plaintiff Graceway's motion for a preliminary injunction. Graceway filed suit in…

    By James DeGiulio — Medicis' Solodyn Patent Upheld on Reexamination The U.S. Patent and Trademark Office has issued a reexamination certificate reaffirming Medicis' U.S. Patent No. 5,908,838 covering the skin treatment Solodyn.  The '838 patent, which issued in June 1999 and has been asserted in several infringement suits, covers a slow-dissolving form of tetracycline,…

    By James DeGiulio — Endo Settles with Impax and Sandoz in Opana Patent Suits Endo Pharmaceuticals Inc. has settled patent infringement suits against Sandoz Inc. and Impax Laboratories Inc. over generic versions of painkiller Opana ER.  The agreement allows Impax to begin selling a version of the drug on January 1, 2013, and allows Sandoz to enter the…

    By James DeGiulio — Celgene, Barr Resolve Patent Dispute over Generic Thalomid Celgene Corp. and Barr Laboratories Inc. have resolved their patent dispute over the multiple myeloma cancer drug Thalomid, with Celgene agreeing to drop its patent infringement claims and Barr dropping its invalidity and antitrust claims. Celgene initiated the dispute in January 2007,…

    By James DeGiulio — Covidien's Patent for Restoril Found Obvious Covidien PLC suffered a setback in its infringement suit with URL Pharma Inc. after the claims of its patent for sleep aid Restoril were found obvious.  In March 2007, Tyco Healthcare Group LP, now Covidien, brought suit against Pharmaceutical Holdings Corp., and its subsidiary…

    By James DeGiulio — Medicis Settles Solodyn Infringement Case with Ranbaxy Medicis Pharmaceutical Corp. has reached consent and licensing agreements with Ranbaxy Laboratories Inc., thus settling patent infringement claims against Ranbaxy over Medicis' oral acne drug Solodyn.  Medicis brought suit in May 2009 after receiving a Paragraph IV letter from Ranbaxy Inc. asserting that…

    By James DeGiulio — Celgene and Novartis Reach Settlement with Barr Laboratories in Ritalin ANDA Suit Celgene Corp. and Novartis AG have reached a settlement with Barr Laboratories Inc. over Barr's attempt to market a generic version of the ADHD drug Ritalin.  Celgene and Novartis brought suit claiming infringement of Celgene's U.S. Patent Nos.…